How do the CANMAT 2023 guidelines address treatment-resistant depression in adults?
Open MIND June 19, 2026 DOI: 10.5281/zenodo.20760604 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical practice guidelines Peer reviewed |
|---|---|
| Population | Adults with TRD |
| Interventions | rTMS lithium ketamine esketamine |
| Topics | Depression |
| Keywords | Depression economics Variety cybernetics Medline Mental health Disease |
| Key points | The CANMAT 2023 guidelines recommend rTMS, lithium, and limited use of ketamine and esketamine for treatment-resistant depression, while noting the need for more research on long-term outcomes. |
Abstract
The CANMAT 2023 guidelines for treatment-resistant depression incorporate a variety of pharmacological and non-pharmacological strategies, reflecting evidence-based options like rTMS, lithium, and modest use of ketamine and esketamine, while highlighting the need for further studies on long-term efficacy.